1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Drugs In Development, 2022, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There is no specific treatment for yellow fever but can be treated to relieve the symptoms.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Yellow Fever - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Yellow Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 4, 9 and 5 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 3 molecules, respectively.
Yellow Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Yellow Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Yellow Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Yellow Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Yellow Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Yellow Fever (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Yellow Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Yellow Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Yellow Fever - Overview
- Yellow Fever - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Yellow Fever - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Yellow Fever - Companies Involved in Therapeutics Development
- Bavarian Nordic A/S
- BioCryst Pharmaceuticals Inc
- Biological E Ltd
- China National Pharmaceutical Group Corp
- Collaborations Pharmaceuticals Inc
- Curevac NV
- Emergex Vaccines Holding Ltd
- Ennaid Therapeutics LLC
- Fab’entech SA
- iBio Inc
- Imutex Ltd
- Inventprise LLC
- Mabloc LLC
- Medigen Inc
- Najit Technologies Inc
- Sanofi
- Serum Institute of India Pvt Ltd
- SmartBioTech
- Theravectys SA
- Tychan Pte Ltd
- Universal Stabilization Technologies Inc
- Yellow Fever - Drug Profiles
- AGS-v PLUS - Drug Profile
- Product Description
- Mechanism Of Action
- Drug for Yellow Fever - Drug Profile
- Product Description
- Mechanism Of Action
- EMX-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ETxR-12 - Drug Profile
- Product Description
- Mechanism Of Action
- FDX-000 - Drug Profile
- Product Description
- Mechanism Of Action
- flavivirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- galidesivir - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Hydrovax-YFV - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibodies for Yellow fever - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SinSaVak - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Yellow Fever - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
- Product Description
- Mechanism Of Action
- SP-0218 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Synthetic Peptides for Yellow Fever - Drug Profile
- Product Description
- Mechanism Of Action
- TY-014 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- yellow fever vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- Yellow Fever - Dormant Projects
- Yellow Fever - Product Development Milestones
- Featured News & Press Releases
- Apr 07, 2022: Emergex signs agreement with ATCC to advance studies of its yellow fever booster vaccine candidate
- Aug 19, 2020: Emergex and Bio-Manguinhos/Fiocruz elucidate T cell epitopes produced by commercial yellow fever vaccine
- Jul 30, 2020: SMART Researchers develop potential antibody treatment for yellow fever in seven months
- Jul 29, 2020: NEJM study demonstrates safety and efficacy of first novel monoclonal antibody specifically developed to treat yellow fever
- Nov 18, 2019: WuXi Biologics congratulates Tychan on the world's first yellow fever antibody tested safe and efficacious in human volunteers
- May 09, 2019: BioCryst completes Phase 1 clinical trial of galidesivir
- Jan 02, 2019: BioCryst initiates phase 1 clinical trial of Galidesivir
- Dec 13, 2018: WuXi Biologics congratulates Tychan on first-in-class monoclonal antibody for Yellow fever after record 7 months of development
- Dec 06, 2018: Tychan Begins Phase I Trials for First Ever Yellow Fever Drug
- Sep 17, 2018: BioCryst receives additional $3.5 million to fund clinical trials of Galidesivir in Yellow Fever
- Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
- Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Yellow Fever, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Yellow Fever - Pipeline by Bavarian Nordic A/S, 2022
- Yellow Fever - Pipeline by BioCryst Pharmaceuticals Inc, 2022
- Yellow Fever - Pipeline by Biological E Ltd, 2022
- Yellow Fever - Pipeline by China National Pharmaceutical Group Corp, 2022
- Yellow Fever - Pipeline by Collaborations Pharmaceuticals Inc, 2022
- Yellow Fever - Pipeline by Curevac NV, 2022
- Yellow Fever - Pipeline by Emergex Vaccines Holding Ltd, 2022
- Yellow Fever - Pipeline by Ennaid Therapeutics LLC, 2022
- Yellow Fever - Pipeline by Fab’entech SA, 2022
- Yellow Fever - Pipeline by iBio Inc, 2022
- Yellow Fever - Pipeline by Imutex Ltd, 2022
- Yellow Fever - Pipeline by Inventprise LLC, 2022
- Yellow Fever - Pipeline by Mabloc LLC, 2022
- Yellow Fever - Pipeline by Medigen Inc, 2022
- Yellow Fever - Pipeline by Najit Technologies Inc, 2022
- Yellow Fever - Pipeline by Sanofi, 2022
- Yellow Fever - Pipeline by Serum Institute of India Pvt Ltd, 2022
- Yellow Fever - Pipeline by SmartBioTech, 2022
- Yellow Fever - Pipeline by Theravectys SA, 2022
- Yellow Fever - Pipeline by Tychan Pte Ltd, 2022
- Yellow Fever - Pipeline by Universal Stabilization Technologies Inc, 2022
- Yellow Fever - Dormant Projects, 2022
- Yellow Fever - Dormant Projects, 2022 (Contd..1)
List of Figures
- Number of Products under Development for Yellow Fever, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bavarian Nordic A/S
- BioCryst Pharmaceuticals Inc
- Biological E Ltd
- China National Pharmaceutical Group Corp
- Collaborations Pharmaceuticals Inc
- Curevac NV
- Emergex Vaccines Holding Ltd
- Ennaid Therapeutics LLC
- Fab’entech SA
- iBio Inc
- Imutex Ltd
- Inventprise LLC
- Mabloc LLC
- Medigen Inc
- Najit Technologies Inc
- Sanofi
- Serum Institute of India Pvt Ltd
- SmartBioTech
- Theravectys SA
- Tychan Pte Ltd
- Universal Stabilization Technologies Inc
